University of Michigan Rogel Cancer Center


The University of Michigan Rogel Cancer Center is a cancer research and treatment institution based in Ann Arbor, Michigan, United States. The Rogel Cancer Center is affiliated with the University of Michigan and Michigan Medicine.

History

The Rogel Cancer Center was founded in 1986 at the University of Michigan. In 1988, it was designated as part of the National Cancer Institute cancer centers program. It received comprehensive cancer center status in 1991 and continues to be an NCI-designated comprehensive cancer center today..
From 1991-2018 it was known as the University of Michigan Comprehensive Cancer Center. The center was renamed the Rogel Cancer Center in 2018 in recognition of a $150 million commitment from Richard and Susan Rogel.
The Rogel Cancer Center is ranked among the top cancer programs by U.S. News & World Report. In addition to being an NCI-designated comprehensive cancer center, it is a founding member of the National Comprehensive Cancer Network
The center’s founding director was Max Wicha, M.D., a medical oncologist and researcher who was part of the team to first discover cancer stem cells in a solid tumor. Wicha served as director for 27 years. He was succeeded by Theodore S. Lawrence, M.D., Ph.D., in 2015 and by Eric Fearon, M.D., Ph.D., in 2016. Fearon is a nationally recognized investigator in cancer genetics whose research has led to a greater understanding of the gene defects that cause colon and rectal cancer to develop and spread.

Scientific programs

Research at the Rogel Cancer Center is divided into seven basic, clinical and population science programs:
Significant cancer research discoveries from the Rogel Cancer Center include: